open access

Vol 46, No 4 (2008)
ORIGINAL PAPERS
Published online: 2009-01-15
Submitted: 2011-12-19
Get Citation

Molecular markers (c-erbB-2, p53) in breast cancer.

Anil Kumar Agrawal, Michał Jeleń, Jerzy Rudnicki, Zygmunt Grzebieniak, Piotr Zukrowski, Ewa Nienartowicz
DOI: 10.2478/v10042-008-0059-7
·
Folia Histochem Cytobiol 2008;46(4):449-455.

open access

Vol 46, No 4 (2008)
ORIGINAL PAPERS
Published online: 2009-01-15
Submitted: 2011-12-19

Abstract

The aim of our study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues. Breast cancer tissue was obtained from 184 female subjects with primary breast cancer. According to hormonal status patients were divided into two groups - 64 belonged to the premenopausal group and 120 to postmenopausal group. Each patient underwent mammectomy and axillary lymphadenectomy. c-erbB-2 protooncogene was detected in 54% cases, and was correlated with infiltrating type of cancer growth, as well as larger tumor size. The presence of p53 antioncogene was observed only in 33% of cases, mainly in infiltrating duct carcinomas. The incidence of c-erbB-2 and p53 positive cases was higher among subjects, whose ultrasound and mammography revealed malignancy. There was no correlation found between of c-erbB-2 expression and axillary lymph nodes involvement It seems probable, that c-erbB-2 and p53 status of cancer tissue may prove to be useful in assessment of the level of biological aggressiveness in breast carcinomas and hence can be used as a prognostic factor.

Abstract

The aim of our study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues. Breast cancer tissue was obtained from 184 female subjects with primary breast cancer. According to hormonal status patients were divided into two groups - 64 belonged to the premenopausal group and 120 to postmenopausal group. Each patient underwent mammectomy and axillary lymphadenectomy. c-erbB-2 protooncogene was detected in 54% cases, and was correlated with infiltrating type of cancer growth, as well as larger tumor size. The presence of p53 antioncogene was observed only in 33% of cases, mainly in infiltrating duct carcinomas. The incidence of c-erbB-2 and p53 positive cases was higher among subjects, whose ultrasound and mammography revealed malignancy. There was no correlation found between of c-erbB-2 expression and axillary lymph nodes involvement It seems probable, that c-erbB-2 and p53 status of cancer tissue may prove to be useful in assessment of the level of biological aggressiveness in breast carcinomas and hence can be used as a prognostic factor.
Get Citation
About this article
Title

Molecular markers (c-erbB-2, p53) in breast cancer.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 46, No 4 (2008)

Pages

449-455

Published online

2009-01-15

DOI

10.2478/v10042-008-0059-7

Bibliographic record

Folia Histochem Cytobiol 2008;46(4):449-455.

Authors

Anil Kumar Agrawal
Michał Jeleń
Jerzy Rudnicki
Zygmunt Grzebieniak
Piotr Zukrowski
Ewa Nienartowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl